About Incyclix Bio
Incyclix Bio is a next-generation cell cycle control company, advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor in clinical development.
Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive targets across many tumor types, including ovarian, breast and lung cancers. Headquartered in Research Triangle Park, NC, Incyclix Bio is founded by pioneers in CDK inhibitor discovery, research and development.
Meet the Team
The founding members of the Incyclix Bio team have unparalleled expertise in developing selective CDK inhibitors and a proven track record of successfully developing novel therapeutics to advance patient care.
February 28, 2023
Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Advanced or Metastatic Cancer
Read More >
March 31, 2022
Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital
Read More >